Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-09
-
Cyclopamine: Advanced Insights into Hedgehog Pathway Inhi...
2025-09-29
Discover the multifaceted applications of Cyclopamine as a potent Hedgehog signaling inhibitor in cancer and developmental biology. This article explores novel mechanistic insights, translational implications, and experimental considerations, offering a deeper perspective for researchers seeking advanced understanding.
-
Dlin-MC3-DMA: Unveiling Its Pivotal Role in Next-Gen mRNA...
2025-09-28
Explore the critical role of Dlin-MC3-DMA as an ionizable cationic liposome for advanced lipid nanoparticle siRNA delivery and mRNA drug delivery lipid platforms. This article offers a unique, mechanistically focused analysis of endosomal escape, formulation science, and translational impact beyond current literature.
-
GSK126: Unveiling EZH2 Inhibition for Epigenetic Precisio...
2025-09-27
Explore the cutting-edge science of GSK126, a selective EZH2 inhibitor, and its role in cancer epigenetics research. This article uniquely examines mechanistic insights, advanced applications, and the integration of lncRNA regulatory pathways for innovative oncology drug development.
-
SM-164: Decoding IAP Antagonism and Apoptosis in Precisio...
2025-09-26
Explore how SM-164, a bivalent Smac mimetic and potent IAP antagonist for cancer therapy, enables advanced dissection of apoptosis induction in tumor cells. This article uniquely integrates recent mechanistic insights and translational research strategies, setting it apart from standard reviews.
-
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit: Precisio...
2025-09-25
Explore how the HyperScribe T7 High Yield Cy3 RNA Labeling Kit empowers advanced in vitro transcription RNA labeling for functional transcriptomics. This article uniquely integrates mechanistic insight, application in gene regulatory studies, and expert comparison with alternative fluorescent RNA probe synthesis methods.
-
ISRIB (trans-isomer): Pioneering Translational Control in...
2025-09-24
Explore how ISRIB (trans-isomer), a potent integrated stress response inhibitor, is reshaping ER stress research and advancing models of fibrosis and cognitive enhancement. This article provides unique insight into mechanistic innovations and translational applications for ISRIB (trans-isomer).
-
Optimizing Genotyping Workflows: Single-Tube DNA Extracti...
2025-09-23
Explore how the Genotyping Kit for target alleles of insects, tissues, fishes and cells streamlines rapid genomic DNA preparation and PCR amplification for multi-species research, minimizing sample cross-contamination and bypassing phenol extraction.
-
Pseudo-modified Uridine Triphosphate: Enhancing mRNA Stab...
2025-09-22
Explore how pseudo-modified uridine triphosphate (Pseudo-UTP) transforms mRNA synthesis with pseudouridine modification, improving RNA stability, translation efficiency, and immune evasion—key factors for mRNA vaccine development and gene therapy.
-
Cyclopamine as a Smoothened Receptor Antagonist in Develo...
2025-09-19
Explore the multifaceted applications of cyclopamine, a potent Hedgehog signaling inhibitor, in developmental biology and cancer research. This article highlights its mechanisms as a Smoothened receptor antagonist, its effects in breast and colorectal cancer models, and its utility in teratogenicity studies.
-
Rucaparib (AG-014699): Modulating DNA Damage Response in ...
2025-09-18
Explore the advanced applications of Rucaparib (AG-014699, PF-01367338), a potent PARP inhibitor, in DNA damage response and radiosensitization in PTEN-deficient and ETS-fusion expressing cancer models. This article highlights its mechanistic roles in base excision repair pathway inhibition and interprets emerging cell death signaling insights relevant to cancer biology research.
-
Several ceritinib resistant mutations following the second l
2025-03-03
Several ceritinib-resistant mutations following the second-line treatment of ALK+-NSCLC have been discovered [64]. These mutations include C1156Y, F1174L, and L1152R, which were first observed in crizotinib-resistant tumor samples. The G1202R ceritinib-resistant mutation occurs within the hinge and
-
br Introduction Psychostimulant abuse and
2025-03-03
Introduction Psychostimulant abuse and addiction remain a societal problem in the United States. The latest statistics from the National Survey on Drug Use and Health indicate that slightly less than one million people over the age of 12 report having a cocaine use disorder (NSDUH, 2016). Additio
-
The rank order of agonist
2025-03-03
The rank order of agonist potency in turkey cardiac chambers demonstrated the predominant presence of the β-adrenergic receptor subtype, in line with the receptor classification by . However, a previous radioligand binding study in the left ventricles of 7-week old turkeys reported the existence of
-
ACK has been clearly implicated in cancer progression in
2025-03-03
ACK1 has been clearly implicated in cancer progression in recent years. A strong correlation between ACK1 gene copy number, protein level and activity have been demonstrated in tumors of different tissue types (Mahajan et al., 2007; van der Horst et al., 2005; Wang et al., 2006). Our western blot a
-
br Acknowledgement br Introduction There
2025-03-03
Acknowledgement Introduction There has been great progress in the treatment of autoimmune disease during the past several decades. However, the majority of autoimmune diseases have no known cure. B lymphocytes and autoantibodies play important roles in many autoimmune diseases, including rheum